Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00147680




Registration number
NCT00147680
Ethics application status
Date submitted
6/09/2005
Date registered
7/09/2005
Date last updated
2/02/2012

Titles & IDs
Public title
Uterine Papillary Serous Cancer (UPSC) Trial
Scientific title
Prospective, Non-randomised Phase 2 Clinical Trial of Carboplatin Plus Paclitaxel With Sequential Radical Pelvic Radiotherapy for Uterine Serous Papillary Cancer
Secondary ID [1] 0 0
UPSC - 001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Uterine Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Womb (Uterine or endometrial cancer)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Paclitaxel, Carboplatin

Treatment: Drugs: Paclitaxel, Carboplatin
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To assess the safety and efficacy of the combination of paclitaxel and carboplatin plus/minus (+/-) pelvic radiotherapy in the treatment of UPSC
Timepoint [1] 0 0
Primary outcome [2] 0 0
To observe the patterns of recurrence following the administration of the combination of paclitaxel and carboplatin +/- pelvic radiotherapy in the treatment of UPSC
Timepoint [2] 0 0
Secondary outcome [1] 0 0
To assess the quality of life (QOL), overall survival and disease free survival
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
- Patients with histologically confirmed UPSC at surgical stage 1b to 4 disease. The
serous-papillary component of the specimen must be at least 30 percent. Patients with
surgical stage 1a disease should not be enrolled.

- Females aged >= 18 years old.

- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.

- Patients may not have received any prior chemotherapy regimens for UPSC.

- Patients must have adequate bone marrow, renal, hepatic and neurologic function.

- Patients must be informed of the investigational nature of the study and sign an
informed consent form.

- Patients with previous malignancy are eligible only if the patient has been
disease-free for >= 5 years.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with pre-existing >= grade 2 neurotoxicity.

- Patients with uncontrolled hypertension, (systolic blood pressure >180 mm Hg or
diastolic blood pressure >100 mm Hg) or uncontrolled cardiac arrhythmia or diabetes
mellitus

- Patients with a history of other malignancy within the last 5 years that could affect
the diagnosis or assessment of UPSC.

- Patients who have a history of serious cardiac disease that is not adequately
controlled are not allowed. Patients with documented myocardial infarction within 6
months preceding study entry; congestive heart failure; unstable angina; a clinically
significant pericardial effusion; or arrhythmias are also ineligible.

- Patients with an active serious infection or other serious underlying medical
condition that would otherwise impair their ability to receive protocol treatment.

- Serious medical or psychiatric illnesses that would prevent informed consent. Dementia
or significantly altered mental status that would prohibit the understanding and/or
giving of informed consent.

- Patients with prior significant allergic reactions to drugs containing cremophor, such
as cyclosporine, or vitamin K are not eligible. A significant reaction may be defined
as, but is not limited to, the description of grade >= 3 allergic reactions using the
Common Toxicity Criteria (CTC). Patients with known hypersensitivity to paclitaxel,
carboplatin or Cremophor EL.

- Patients who have received prior whole pelvis radiotherapy.

- Patients with uncontrolled pelvic inflammatory disease that would contraindicate
pelvic radiotherapy.

- Patients who are pregnant or breast-feeding.

- Patients receiving other investigational therapy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2004
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2009
Sample size
Target
30
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
QCGC, Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [2] 0 0
Mater Adult Public Hospital - South Brisbane
Recruitment postcode(s) [1] 0 0
4029 - Herston
Recruitment postcode(s) [2] 0 0
4101 - South Brisbane

Funding & Sponsors
Primary sponsor type
Other
Name
Queensland Centre for Gynaecological Cancer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will be an open, non-randomised, clinical phase 2 trial, which will involve 30
women diagnosed with uterine papillary serous cancer. The researchers will investigate the
effect of four cycles of paclitaxel/carboplatin, followed by whole pelvic external beam
radiotherapy to a standard pelvis field (50.4 Gy) with or without a para-aortic boost with
respect to the safety and efficacy of treatment, and patterns of recurrence.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00147680
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Andreas Obermair
Address 0 0
QCGC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00147680